{"id":"amg102","safety":{"commonSideEffects":[{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1743063","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It acts as a decoy receptor for TNF-alpha, thereby inhibiting the interaction between TNF-alpha and its natural receptors, which are involved in the inflammatory response and tumor growth.","oneSentence":"AMG102 is a recombinant human tumor necrosis factor (TNF) receptor fusion protein.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:08:46.085Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT00791154","phase":"PHASE1, PHASE2","title":"QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer","status":"TERMINATED","sponsor":"NantCell, Inc.","startDate":"2008-12-02","conditions":"Lung Cancer, Small Cell Lung Cancer, Solid Tumors","enrollment":213},{"nctId":"NCT00788957","phase":"PHASE1, PHASE2","title":"Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)","status":"COMPLETED","sponsor":"NantBioScience, Inc.","startDate":"2008-10-27","conditions":"Colon Cancer, Colorectal Cancer, Gastrointestinal Cancer","enrollment":177},{"nctId":"NCT02154490","phase":"","title":"Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2014-07-08","conditions":"Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7","enrollment":1864},{"nctId":"NCT01443065","phase":"PHASE2","title":"MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2011-01","conditions":"Malignant Neoplasm of Esophagus, Malignant Neoplasm of Stomach","enrollment":162},{"nctId":"NCT02926638","phase":"PHASE2, PHASE3","title":"Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2014-06-16","conditions":"MET Positive, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7","enrollment":9},{"nctId":"NCT01039207","phase":"PHASE2","title":"Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2010-10","conditions":"Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma","enrollment":31},{"nctId":"NCT01233687","phase":"PHASE1, PHASE2","title":"AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Ahmad Tarhini","startDate":"2011-08","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":49},{"nctId":"NCT02137343","phase":"PHASE3","title":"A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer","status":"TERMINATED","sponsor":"Amgen","startDate":"2014-07","conditions":"Gastric Cancer","enrollment":34},{"nctId":"NCT01791374","phase":"PHASE1","title":"Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-11","conditions":"Part 1- Advanced Solid Tumors, Part 2- Advanced or Metastatic Gastric Cancer, Part 2- Advanced or Metastatic GEJ","enrollment":21},{"nctId":"NCT01697072","phase":"PHASE3","title":"First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma","status":"TERMINATED","sponsor":"Amgen","startDate":"2012-10","conditions":"Gastric Cancer","enrollment":609},{"nctId":"NCT01113398","phase":"PHASE2","title":"AMG 102 and Avastin for Recurrent Malignant Glioma","status":"COMPLETED","sponsor":"Katy Peters","startDate":"2010-08","conditions":"Glioblastoma Multiforme, Gliosarcoma","enrollment":36},{"nctId":"NCT00427440","phase":"PHASE2","title":"A Phase II Study to Treat Advanced Malignant Glioma","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-11","conditions":"Advanced Malignant Glioma","enrollment":61},{"nctId":"NCT00422019","phase":"PHASE2","title":"A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-01","conditions":"Advanced Renal Cell Carcinoma","enrollment":61},{"nctId":"NCT00770848","phase":"PHASE1, PHASE2","title":"AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-11","conditions":"Cancer, Castrate-Resistant Prostate Cancer, Mestastatic Prostate Cancer","enrollment":162},{"nctId":"NCT00719550","phase":"PHASE1, PHASE2","title":"AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-02","conditions":"Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer","enrollment":130},{"nctId":"NCT01105390","phase":"PHASE2","title":"AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2010-04","conditions":"Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rilotumumab"],"phase":"phase_2","status":"active","brandName":"AMG102","genericName":"AMG102","companyName":"UNICANCER","companyId":"unicancer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AMG102 is a recombinant human tumor necrosis factor (TNF) receptor fusion protein. Used for Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}